BACKGROUND: While certain inherited syndromes (e.g. Neurofibromatosis or Li-Fraumeni) are associated with an increased risk of glioma, most familial gliomas are non-syndromic. This study describes the demographic and clinical characteristics of the largest series of non-syndromic glioma families ascertained from 14 centres in the United States (US), Europe and Israel as part of the Gliogene Consortium. METHODS: Families with 2 or more verified gliomas were recruited between January 2007 and February 2011. Distributions of demographic characteristics and clinical variables of gliomas in the families were described based on information derived from personal questionnaires. FINDINGS: The study population comprised 841 glioma patients identified in 376 families (9797 individuals). There were more cases of glioma among males, with a male to female ratio of 1.25. In most families (83%), 2 gliomas were reported, with 3 and 4 gliomas in 13% and 3% of the families, respectively. For families with 2 gliomas, 57% were among 1st-degree relatives, and 31.5% among 2nd-degree relatives. Overall, the mean (±standard deviation [SD]) diagnosis age was 49.4 (±18.7) years. In 48% of families with 2 gliomas, at least one was diagnosed at <40y, and in 12% both were diagnosed under 40y of age. Most of these families (76%) had at least one grade IV glioblastoma multiforme (GBM), and in 32% both cases were grade IV gliomas. The most common glioma subtype was GBM (55%), followed by anaplastic astrocytoma (10%) and oligodendroglioma (8%). Individuals with grades I-II were on average 17y younger than those with grades III-IV. INTERPRETATION: Familial glioma cases are similar to sporadic cases in terms of gender distribution, age, morphology and grade. Most familial gliomas appear to comprise clusters of two cases suggesting low penetrance, and that the risk of developing additional gliomas is probably low. These results should be useful in the counselling and clinical management of individuals with a family history of glioma.
BACKGROUND: While certain inherited syndromes (e.g. Neurofibromatosis or Li-Fraumeni) are associated with an increased risk of glioma, most familial gliomas are non-syndromic. This study describes the demographic and clinical characteristics of the largest series of non-syndromic glioma families ascertained from 14 centres in the United States (US), Europe and Israel as part of the Gliogene Consortium. METHODS: Families with 2 or more verified gliomas were recruited between January 2007 and February 2011. Distributions of demographic characteristics and clinical variables of gliomas in the families were described based on information derived from personal questionnaires. FINDINGS: The study population comprised 841 gliomapatients identified in 376 families (9797 individuals). There were more cases of glioma among males, with a male to female ratio of 1.25. In most families (83%), 2 gliomas were reported, with 3 and 4 gliomas in 13% and 3% of the families, respectively. For families with 2 gliomas, 57% were among 1st-degree relatives, and 31.5% among 2nd-degree relatives. Overall, the mean (±standard deviation [SD]) diagnosis age was 49.4 (±18.7) years. In 48% of families with 2 gliomas, at least one was diagnosed at <40y, and in 12% both were diagnosed under 40y of age. Most of these families (76%) had at least one grade IV glioblastoma multiforme (GBM), and in 32% both cases were grade IV gliomas. The most common glioma subtype was GBM (55%), followed by anaplastic astrocytoma (10%) and oligodendroglioma (8%). Individuals with grades I-II were on average 17y younger than those with grades III-IV. INTERPRETATION:Familial glioma cases are similar to sporadic cases in terms of gender distribution, age, morphology and grade. Most familial gliomas appear to comprise clusters of two cases suggesting low penetrance, and that the risk of developing additional gliomas is probably low. These results should be useful in the counselling and clinical management of individuals with a family history of glioma.
Authors: Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler Journal: Cancer Date: 2008-10-01 Impact factor: 6.860
Authors: Sanjay Shete; Ching C Lau; Richard S Houlston; Elizabeth B Claus; Jill Barnholtz-Sloan; Rose Lai; Dora Il'yasova; Joellen Schildkraut; Siegal Sadetzki; Christoffer Johansen; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Ping Yang; Nicholas A Vick; Margaret Wrensch; Faith G Davis; Bridget J McCarthy; Eastwood Hon-chiu Leung; Caleb Davis; Rita Cheng; Fay J Hosking; Georgina N Armstrong; Yanhong Liu; Robert K Yu; Roger Henriksson; Beatrice S Melin; Melissa L Bondy Journal: Cancer Res Date: 2011-10-28 Impact factor: 12.701
Authors: Anita Villani; Uri Tabori; Joshua Schiffman; Adam Shlien; Joseph Beyene; Harriet Druker; Ana Novokmet; Jonathan Finlay; David Malkin Journal: Lancet Oncol Date: 2011-05-19 Impact factor: 41.316
Authors: Michael E Scheurer; Carol J Etzel; Mei Liu; Jill Barnholtz-Sloan; Fredrik Wiklund; Björn Tavelin; Margaret R Wrensch; Beatrice S Melin; Melissa L Bondy Journal: Am J Epidemiol Date: 2010-09-21 Impact factor: 4.897
Authors: Steven Hsu; Marisa Quattrone; Quinn Ostrom; Timothy C Ryken; Andrew E Sloan; Jill S Barnholtz-Sloan Journal: J Neurosurg Spine Date: 2011-03-11
Authors: Joseph A Osorio; Shawn L Hervey-Jumper; Kyle M Walsh; Jennifer L Clarke; Nicholas A Butowski; Michael D Prados; Mitchel S Berger Journal: J Neurooncol Date: 2014-09-11 Impact factor: 4.130
Authors: Daniel I Jacobs; Kazutaka Fukumura; Matthew N Bainbridge; Georgina N Armstrong; Spiridon Tsavachidis; Xiangjun Gu; Harsha V Doddapaneni; Jianhong Hu; Joy C Jayaseelan; Donna M Muzny; Jason T Huse; Melissa L Bondy Journal: Neuro Oncol Date: 2018-11-12 Impact factor: 12.300
Authors: Vanessa Y Ruiz; Corinne E Praska; Georgina Armstrong; Thomas M Kollmeyer; Seiji Yamada; Paul A Decker; Matthew L Kosel; Jeanette E Eckel-Passow; Daniel H Lachance; Matthew N Bainbridge; Beatrice S Melin; Melissa L Bondy; Robert B Jenkins Journal: Neuro Oncol Date: 2018-05-18 Impact factor: 13.029
Authors: Rhiannon E Lloyd; Kathleen Keatley; D Timothy J Littlewood; Brigitte Meunier; William V Holt; Qian An; Samantha C Higgins; Stavros Polyzoidis; Katie F Stephenson; Keyoumars Ashkan; Helen L Fillmore; Geoffrey J Pilkington; John E McGeehan Journal: Neuro Oncol Date: 2015-03-02 Impact factor: 12.300
Authors: Ali Jalali; E Susan Amirian; Matthew N Bainbridge; Georgina N Armstrong; Yanhong Liu; Spyros Tsavachidis; Shalini N Jhangiani; Sharon E Plon; Ching C Lau; Elizabeth B Claus; Jill S Barnholtz-Sloan; Dora Il'yasova; Joellen Schildkraut; Francis Ali-Osman; Siegal Sadetzki; Christoffer Johansen; Richard S Houlston; Robert B Jenkins; Daniel Lachance; Sara H Olson; Jonine L Bernstein; Ryan T Merrell; Margaret R Wrensch; Faith G Davis; Rose Lai; Sanjay Shete; Kenneth Aldape; Christopher I Amos; Donna M Muzny; Richard A Gibbs; Beatrice S Melin; Melissa L Bondy Journal: Sci Rep Date: 2015-02-05 Impact factor: 4.379
Authors: Matthew N Bainbridge; Georgina N Armstrong; M Monica Gramatges; Alison A Bertuch; Shalini N Jhangiani; Harsha Doddapaneni; Lora Lewis; Joseph Tombrello; Spyros Tsavachidis; Yanhong Liu; Ali Jalali; Sharon E Plon; Ching C Lau; Donald W Parsons; Elizabeth B Claus; Jill Barnholtz-Sloan; Dora Il'yasova; Joellen Schildkraut; Francis Ali-Osman; Siegal Sadetzki; Christoffer Johansen; Richard S Houlston; Robert B Jenkins; Daniel Lachance; Sara H Olson; Jonine L Bernstein; Ryan T Merrell; Margaret R Wrensch; Kyle M Walsh; Faith G Davis; Rose Lai; Sanjay Shete; Kenneth Aldape; Christopher I Amos; Patricia A Thompson; Donna M Muzny; Richard A Gibbs; Beatrice S Melin; Melissa L Bondy Journal: J Natl Cancer Inst Date: 2014-12-07 Impact factor: 11.816